Morgan Stanley views CVS‘s path to Medicare Advantage margin recovery as underappreciated, though risks remain, the analyst tells investors in a research note. The firm, which has an Overweight rating and $80 price target on CVS shares, thinks CVS could have the “cleanest” Q2 and should be favorably positioned in light of competitive dynamics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health’s Growth Potential and Strategic Positioning Justify Buy Rating Amid Market Challenges
- Judge orders CVS’ Omnicare to pay $949M over invalid prescriptions, Reuters says
- Pressure continues to mount on health insurers as costs rise, WSJ says
- JPMorgan says too early to conclude other MCOs exposed to same risk as Centene
- Wells says OBBBA incrementally positive for managed care, uncertainty still high